ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups

por Quinn, D.I., Ng, C.F., Grande, E., Kwon, T.G., Linke, R., Lee, J.-L., Rosbrook, B., Thakur, M.N., Eto, M., Gross-Goupil, M.
Publicado 2021